Literature DB >> 10982759

A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia.

J Hamilton1, E Guthrie, F Creed, D Thompson, B Tomenson, R Bennett, K Moriarty, W Stephens, R Liston.   

Abstract

BACKGROUND & AIMS: This study aimed to determine whether brief psychodynamic-interpersonal (PI) psychotherapy is more efficacious than a psychological control for patients with chronic, intractable functional dyspepsia (FD), and whether patients with abnormal gastric function respond differently than those with normal gastric function.
METHODS: Ninety-five consecutive patients with chronic symptoms of FD who had failed to respond to conventional pharmacologic treatments were approached. Thirty-seven received PI psychotherapy, and 36 the control condition (supportive therapy). Patients completed self-report questionnaires before and after treatment and 12 months later. The patients' gastroenterologists, who were blind to the study groups, conducted independent ratings before and after treatment. Forty-nine patients also underwent a radioisotope gastric emptying study. An intention-to-treat analysis was used with baseline scores as covariates.
RESULTS: At the end of treatment, there were significant advantages for PI psychotherapy compared with controls for the gastroenterologists' (P = 0.002) and patients' total symptom score (P = 0.015). One year after treatment, the symptomatic scores were similar. However, a subanalysis showed that PI therapy was superior to the control condition at 1 year, when patients with severe heartburn were excluded. There was no difference in outcome between patients with normal and abnormal gastric emptying.
CONCLUSIONS: PI therapy may have both short- and long-term effects in patients with dyspepsia, but further evaluation is required. Its cost-effectiveness needs to be determined.

Entities:  

Mesh:

Year:  2000        PMID: 10982759     DOI: 10.1053/gast.2000.16493

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

Review 1.  ACG and CAG Clinical Guideline: Management of Dyspepsia.

Authors:  Paul Moayyedi; Brian E Lacy; Christopher N Andrews; Robert A Enns; Colin W Howden; Nimish Vakil
Journal:  Am J Gastroenterol       Date:  2017-06-20       Impact factor: 10.864

2.  Functional dyspepsia.

Authors:  Rita Brun; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

Review 3.  Review article: current treatment options and management of functional dyspepsia.

Authors:  B E Lacy; N J Talley; G R Locke; E P Bouras; J K DiBaise; H B El-Serag; B P Abraham; C W Howden; P Moayyedi; C Prather
Journal:  Aliment Pharmacol Ther       Date:  2012-05-16       Impact factor: 8.171

4.  The effectiveness of psychodynamic psychotherapies: An update.

Authors:  Peter Fonagy
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

5.  Treatment of functional dyspepsia.

Authors:  Smita L S Halder; Nicholas J Talley
Journal:  Curr Treat Options Gastroenterol       Date:  2005-08

6.  Functional Dyspepsia: A New Rome III Paradigm.

Authors:  Smita L S Halder; Nicholas J Talley
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 7.  Current management strategies and emerging treatments for functional dyspepsia.

Authors:  Michael Camilleri; Vincenzo Stanghellini
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-05       Impact factor: 46.802

8.  Treatment of Functional Dyspepsia.

Authors:  Christine Feinle-Bisset; Jane M. Andrews
Journal:  Curr Treat Options Gastroenterol       Date:  2003-08

9.  A validated tool for psychiatric comorbidity in the patients with functional dyspepsia.

Authors:  Jong Chan Lee; Su Jin Hong
Journal:  J Neurogastroenterol Motil       Date:  2010-04-28       Impact factor: 4.924

10.  Effect of childhood adversity on health related quality of life in patients with upper abdominal or chest pain.

Authors:  A-M Biggs; Q Aziz; B Tomenson; F Creed
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.